News

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...
PMLive22h
Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma
Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...
PharmExec17h
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Relapsed or Refractory Multiple Myeloma
Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...
MPR22h
Lynozyfic Approved for Relapsed/Refractory Multiple Myeloma
The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...
Managed Healthcare Executive15h
FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema
Ekterly comes in the form of a 300 mg tablet. The recommended dosage is 600 mg split into two doses taken at the earliest sign of an attack, according to the prescribing information. Additional ...